Real-World Survival Outcomes Associated With First-Line Immunotherapy, Targeted Therapy, and Combination Therapy for Metastatic Clear Cell Renal Cell Carcinoma
Open Access
- 3 May 2021
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 4 (5) , e2111329
Abstract
Renal cell carcinoma (RCC) is the sixth most common cancer among men and the eighth most common cancer among women in the US, accounting for 4.2% of all incident cancer cases and 2.4% of all cancer deaths each year.1 Approximately 30% of patients with RCC present with either regional or distant metastases, and 20% of individuals who receive an initial diagnosis of localized disease will eventually develop regional or distant metastases.1-3 Clear cell RCC is the most common histologic subtype, representing approximately 80% of all RCCs.4Keywords
This publication has 25 references indexed in Scilit:
- Faculty Opinions recommendation of Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.2016
- Nivolumab versus Everolimus in Advanced Renal-Cell CarcinomaNew England Journal of Medicine, 2015
- Temporal Trends and Factors Associated with Systemic Therapy after Cytoreductive Nephrectomy: An Analysis of the National Cancer DatabaseJournal of Urology, 2015
- An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational StudiesMultivariate Behavioral Research, 2011
- Optimal caliper widths for propensity‐score matching when estimating differences in means and differences in proportions in observational studiesPharmaceutical Statistics, 2011
- Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studiesBMJ, 2007
- Generalizability of cancer clinical trial resultsCancer, 2006
- Multiple significance tests: the Bonferroni methodBMJ, 1995
- Adapting a clinical comorbidity index for use with ICD-9-CM administrative databasesJournal of Clinical Epidemiology, 1992
- A new method of classifying prognostic comorbidity in longitudinal studies: Development and validationJournal of Chronic Diseases, 1987